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Abstract
This article provides a commentary, from a community pharmacy perspective, on the policy
environment for the pharmacy sector in Australia, with a particular focus on present challenges
arising from proposals to achieve substantial PBS cost savings from an anticipated surge of new
generic drugs. Some $2 billion of medicines currently on the PBS will come off patent in the next
4 years. This growth comes from a low base where generics currently account for only 15% of the
total PBS budget. Remuneration for PBS dispensing is fixed through five year agreements with the
government, so trading terms on generics are important for the cross-subsidy of other dispensing
activities and professional services. These trading terms (discounts provided by generics suppliers)
have become part of the overall cost and revenue structure of pharmacies. Despite these
arrangements, generic substitution rates in Australia are lower than in most comparable countries,
which the government views as an opportunity to promote generic use. The future of generic drug
supply via the PBS is important to allow consumers access to medications at the lowest possible
price and to provide space for PBS listing of new and expensive drugs. But considerations of PBS
reform need to take account of the role and viability of community pharmacy sector as provider
of pharmaceuticals in a timely and efficient manner to Australian residents.
Background
This article will address some of the issues currently facing
community pharmacy, as a major wave of reforms to the
Pharmaceutical Benefits Scheme (PBS) begins to take
effect focusing on utilising an anticipated surge of new
generic drugs to achieve substantial savings in the overall
cost of the PBS. Community pharmacy comprises some 5
000 pharmacies throughout Australia which are part sup-
pliers of Government funded pharmaceuticals and part
retailers. This dual role is complex and unique, given also
that community pharmacy provides much of the capital
for the infrastructure that facilitates the delivery of phar-
maceutical services to the Australian consumer. As a busi-
ness entity, community pharmacy must ensure that it
operates in a sound commercial environment, so any
changes to the current financial parameters have major
consequences. This article will explain some of the inter-
related and inter-dependent relationships that make up
community pharmacy, in the Australian setting, as the
uptake of new generic drugs increases.
The definition of generic medicines accepted by pharma-
cists, suppliers to pharmacy and the professional organi-
sations, is that generic drugs are originator or innovator
products or products which are equivalent to originator
brands, which are no longer protected by patent [1]. In
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this respect, a generic product range will include freshly
off patent products (a current example would be pravasta-
tin) and a large tail of different brands of older products
(two examples would be amoxycillin and temazepam).
However in the context of discussions of generics policy
and PBS reform, the term generic typically excludes the
off-patent original product and refers only to the alterna-
tive brand(s) marketed by other suppliers (or by the orig-
inal supplier under a generic name).
An application for registration of a generic product gener-
ally includes a bioequivalence study which has the aims of
establishing whether two or more formulations of the
same drug are equivalent in terms of the rate and extent of
absorption of the drug (or active moiety) into the systemic
circulation.
In 1994, changes were made to legislation to permit phar-
macists to substitute generic products for original brand
pharmaceuticals if they are listed on the Schedule of Phar-
maceutical Benefits as being bioequivalent and able to be
substituted, even when the prescription specifies a partic-
ular brand. Under the legislation, substitution must not
occur if the prescriber has indicated that substitution is
not permitted.
Brand substitution may only occur after consultation with
the patient or carer. The patient's health should always be
the pharmacist's prime consideration in any brand substi-
tution decision. Decisions to substitute one brand for
another should not place patients at risk and pharmacists
should endeavour to be consistent in the selection of
brands for patients on long term therapy, to avoid patient
confusion.
Pharmacists should encourage or offer to assist patients to
have their medication regularly reviewed to check for
duplication of different brands of the same medicine.
Generic medicine substitution will grow significantly due
to three factors:
• There is a significant number of medicines that will
become off-patent in the next 4 years. Some $2 billion of
medicines currently on the PBS will come off patent.
• Government cost containment strategies to manage the
growth of the PBS. These programs have been developed
around increased support of generic substitution.
• Increased use of medicines due to an ageing population.
Concession card holders are the most sensitive to the price
benefits of generic brands over the originator products.
Remuneration for pharmacy is fixed because the price to
the consumer is determined by the PBS. Medicines were
priced in 2006 with a mark up of only 10% and a profes-
sional fee of $5.15 and a mark up of 4% or less applies to
items priced over $450 [2]. For pharmacy to remain viable
trading terms are therefore important. The trading terms
relate to efficient purchasing and loyalty. Trading terms
on generic medicines are used to cross-subsidise the bulk
of other dispensing activities and professional services
offered by community pharmacies. These trading terms
include a discount level offered by generics suppliers and
structured for each pharmacy, based around normal busi-
ness drivers. As prices to consumers are fixed, pharmacists
offer additional and varied services to consumers, to dif-
ferentiate their pharmacy offer. Over the past decade,
these trading terms have become part of the overall finan-
cial structure of pharmacies.
Community pharmacy by definition is service and knowl-
edge focused; it is mostly located in convenient locations
and is faced with the rising costs that all businesses face
and some that are industry specific. Prescription business
is a core activity for virtually every pharmacy and accounts
for around 70% of pharmacy turnover.
Recently, various reforms have been introduced, based on
the increased use of the freshly off patent drugs such as
sertraline and simvastatin. The focus is squarely on these
new generic drugs coming off patent as they are high
priced, generally popular with both physicians and
patients because of their improved efficacy compared to
older products, generally have a higher safety index, are
often presented in a dose form that encourages patient
compliance (e.g. once a day dosing instead of three times
a day) and have an acceptable cost to benefit ratio. The
older, unprotected generic drugs are comparatively
cheaper and have a lesser impact on the total costs of the
Pharmaceutical Benefits Scheme.
Government programs and initiatives to increase the dis-
pensing of generic medicines generate tensions when the
financial structure of community pharmacy is such that
increased generics use results in declining remuneration.
Community pharmacy will find some difficulty in adjust-
ing to this new set of government cost containment pres-
sures.
Generic pharmaceutical suppliers
Australia has a relatively small but active competitive
landscape for generic pharmaceuticals with five major
suppliers to the PBS [3]. Whilst a growing market for
generic sales, Australia represents a logistical issue for the
world's biggest generic players. The relatively small size of
the market and high cost of entry make Australia a diffi-
cult investment opportunity for multi-national genericAustralia and New Zealand Health Policy 2007, 4:7 http://www.anzhealthpolicy.com/content/4/1/7
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companies that are structured for high volume markets.
But there is genuine competition in the market place, with
active sales forces encouraging generic supplier loyalty
and encouraging efficient, timely stock purchasing, either
directly from the supplier or through a short line or full
line wholesaler.
The actual supply of generics is a critical issue. The cost of
storage and distribution is a real cost and is part of the
obligation of wholesalers to offer all PBS items to commu-
nity pharmacy, in any part of Australia, within 24 hours.
When a drug is supplied by a full line wholesaler (either
Sigma, API or Symbion) the pharmacist can order and
receive any quantity and that item will be delivered as part
of their next (usually) daily order. If the pharmacist orders
the drug from the generic supplier (direct supply) or a
short line wholesaler (offering a limited range of stock,
usually the top sellers) the order may be subject to a vol-
ume requirement, so that the delivery of the stock is cost
effective.
Considerable effort is expended to entrench supplier loy-
alty as pharmacists are reluctant to change generic suppli-
ers for short term gains. Despite the fact that the generic
marketplace in Australia is dominated by two larger com-
panies, Alphapharm and Sigma Pharmaceuticals, the
smaller generic companies are vigorous and nimble com-
petitors.
Australian generics growth
The average price of a generic is just over $13 while the
average price of a PBS item is just over $40. In Australia,
the growth of generics will exceed the growth of the PBS
but comes from a low base where generics currently
account for only 15% of the total PBS budget. The PBS
growth has now dampened and is predicted not to exceed
the rate of the economy growth for the foreseeable future
[4]. Although only accounting for 15% of PBS dollars one
in four prescriptions presented to pharmacists in Australia
were filled with generic medicines in 2004–05. This level
of use will almost double in the next five years as 58 of the
100 top selling prescription medicines will come off pat-
ent and be substituted by generic branded drugs [3].
A significant market factor is the increasing dominance
that the emerging generics will have over the total dollar
value of the market. By December 2008, 10 of the top 20
drugs will be patent expired. These 10 drugs currently rep-
resent 20% of the total dispensed cost of the PBS, a total
of $1.3 billion and account for 15% of all the PBS pre-
scriptions. At present only 2 of these drugs are patent
expired.
In 2009 over 200 generic drugs will account for a dis-
pensed value of around $2 billion. The top 10 generics
will be responsible for 40% of this value ($800 m) and the
top 40 generics will make up 85% ($1.7 b) [3].
This represents a significant shift in the current structure
of the generic market for manufacturers and pharmacists.
The patent expiry of such high value drugs will drive
increased competition over a small part of the pharmaceu-
tical product range and also concentrate pharmacy generic
activity and profitability. This situation will be manifested
in a numerically small number of generic drugs, com-
pared to both the total generic range and the total number
of listed pharmaceuticals, with a high dollar value and
comprising the significant part of the total cost of the PBS.
A satisfactory level of profitability is crucial for the ongo-
ing survival and development of a competitive generics
market in Australia and most fundamentally, the profita-
bility of the generics market in community pharmacy
underpins the professional service levels and business via-
bility of community pharmacy and hence the welfare of
Australian consumers.
Generic medicines and consumers
When a consumer is supplied a generic medicine, the
price to the consumer is generally lower than the branded
product. This is complicated to an extent if the original
brand medicine does not have a brand price premium (a
manufacturer surcharge). In this situation the consumer
would pay the standard concession price or the standard
general price i.e. the price to the consumer is the same
whether a generic or an original brand is supplied. How-
ever, as many original brands do have a brand price pre-
mium the consequent savings on medicines are of
increasing importance when the consumer is taking mul-
tiple medications, on a long term basis. As the pharmacist
may also be enjoying better trading terms if a generic med-
icine is supplied, it could be assumed that the consumer
would be encouraged to consider using a generic instead
of a branded product. Despite the more favourable trad-
ing terms, generic substitution rates in Australia are lower
than in most comparable countries. It is for this reason the
government wants to promote generic use.
The pharmacist must spend time with the patient to
explain bio equivalence, packaging differences (for exam-
ple compliance style blister strips, carton packaging which
may be significantly different) and ongoing vigilance to
avoid medicine error. The pharmacist must also talk to the
consumer about differing brand names and drug names
so that the patient appreciates the continuity of their med-
icines. The three parties involved in the medicine supply
process (doctor, pharmacist and patient) may all use dif-
ferent names for the medicine, which is confusing and
potentially risky. All these factors will affect compliance to
medicines and therefore will affect health outcomes.Australia and New Zealand Health Policy 2007, 4:7 http://www.anzhealthpolicy.com/content/4/1/7
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Consumers should not be expected to frequently receive a
different brand of the same medicine. Pharmacists con-
sistently balance competitive offers from generic suppliers
with an offer that is reassuring for their patients. Conse-
quently, major regulatory changes by government may
result in unstable market conditions, which can affect
consumers significantly, as pharmacists deal with the
uncertainty of product supply and product pricing.
Generic medicines are no different to branded products in
that patients must be offered counselling every time a pre-
scription is dispensed. It is critical that consumers receive
counselling by the pharmacist with every new medication,
every change in dose and on a regular basis for those per-
manently taking a range of medicines for chronic condi-
tions. Consumer Medicine Information, which provides
an overview of relevant information to encourage effective
medication use by the consumer and also details side
effects and contra indications, is also offered to patients.
Consumer Medicine Information is designed with the
consumer in mind and is quite different to product infor-
mation which is often found inside pharmaceutical pack-
aging, and is written within a technical and legislative
framework.
Generic medicines and government
Government, through the Pharmaceutical Benefits
Scheme, is running a reform agenda to achieve cost sav-
ings and efficiencies in the supply of medicines. Control
in growth of the PBS has been a high priority within Treas-
ury and the Department of Health and Ageing.
Price-volume agreements provide a mechanism for man-
aging potential growth in PBS expenditure. The agree-
ments represent a 'risk sharing' arrangement whereby any
usage greater than an agreed level is subsidised at a lower
price. This agreement recognises the fixed costs involved
in the development of the drug and adjusts reimburse-
ment as volumes increase, with only the variable costs
increasing.
It is worth noting that when the PBS was in rapid growth
– 14 per cent in 1999–00 and 19 per cent in 2000–01, the
main drivers of this growth were the introduction of new
blockbuster drugs onto the PBS, notably Celebrex and
Zyban – and their enthusiastic prescribing by doctors,
often for conditions for which they were not intended
(e.g. 'leakage'). Government policy measure – risk share
and price volume agreements imposed by the PBAC and
PBPA will ensure such cost blowouts will not occur again
[5].
Reference pricing ensures that Government reimburse-
ment is equivalent to the lowest priced drug within each
therapeutic group, known as the benchmark price. Drugs
of similar safety, efficacy and health outcomes are placed
in the same therapeutic groups at the same price and as
new drugs are generally only listed on an equivalence
basis, the size of reference groups is growing. A drug may
only receive a higher subsidised price if the drug can be
demonstrated to have a clinical advantage over alternative
drugs.
Commencing in August 2005, when generic drugs are
listed, the benchmark price is reduced by a mandatory
12.5%. The price reduction affects all brands of the drug
and all forms and strengths of the drug that are adminis-
tered in the same way. It also affects all other drugs which
are deemed to be therapeutically equivalent.
The possibility of introducing a tendering system for the
supply of PBS generics has also been part of the debate [6].
A simplistic attraction of a tendering system is the achieve-
ment of a low price for a set time. Long term ramifications
of a tendering system are however seriously problematic.
Alternative suppliers may simply cease to operate in Aus-
tralia, as suppliers cannot maintain a business presence
bereft of business activity. A single supply source is poten-
tially risky for consumers and the changeover of medicine
supply to consumers would create many difficulties
related to compliance. The removal of an active, competi-
tive market place for generics, as exists currently, changes
the business environment totally. Business environments
work best when competition is unfettered (of course in
the pharmaceutical market, overarching legislative and
professional obligations must be adhered to).
In November 2006, the Pharmacy Guild of Australia
accepted the Government's Pharmaceutical Benefits
Scheme (PBS) Reform Proposals. The Government will
introduce major changes to the PBS. Medicines on the PBS
will be separated into two groups, each subject to different
pricing arrangements. The first group encompasses medi-
cines where there is only a single brand listed (referred to
as F1). This group contains both on patent and off patent
medicines that are not substitutable with other brands or
medicines. There are no mandatory price reductions for
these medicines and existing price linkages are retained
within this group.
The second group includes products for which there are
many brands listed and groups of medicines that are inter-
changeable between patients (referred to as F2). There is
already the requirement for a 12.5 per cent price reduction
when the first new brand of a medicine is listed on the
PBS. From 1 August 2008 a further reduction in the prices
of these medicines will be required:
- a price drop of 2 per cent a year for three years for medi-
cines where price competition between brands is low; andAustralia and New Zealand Health Policy 2007, 4:7 http://www.anzhealthpolicy.com/content/4/1/7
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- A one-off price drop of 25 per cent for medicines where
price competition between brands is high
For example, medicines such as simvastatin, omeprazole,
ranitidine, amoxicillin and felodipine have been identi-
fied as multiple brand medicines where there is high com-
petition. Around 100 molecules currently costing the PBS
$2 billion a year will fall into the high competition group.
The Government will move to a system of price disclosure,
where the price that the Government pays will reflect the
actual price at which the medicine is being sold.
Reference pricing links the price of a medicine to the price
of other medicines that provide a similar health outcome.
It will continue on F1 medicines in reference price groups
and for F2 medicines that are interchangeable between
patients. If a price change occurs for one of these medi-
cines, this will flow to the others. [7].
Generic medicines and pharmacists
Research shows that almost all community pharmacy net
profits and cash flow have been negatively affected in
2005 and 2006 by the triple impacts of zero or negative
PBS script growth, rising overheads and extreme competi-
tion. Data collected by the Pharmacy Guild of Australia
(Guild Digest) and data collected from specialist account-
ing firms with many pharmacy clients (Johnston Rorke)
support this claim [8]. Community pharmacy is no differ-
ent to most retail activities, in that consumers seek com-
petitive pricing. In pharmacy, competitive pricing occurs
in every retail category from health and beauty to over the
counter medicines. Price competition between pharma-
cies is robust. This is occurring as a result of focused mar-
keting efforts by the larger branded or franchised stores,
between the more traditional community pharmacies that
operate under a franchise brand and groups of independ-
ently owned pharmacies that undertake promotional
activities as a collective. In much of the pharmacy market,
there is also competitive activity with other retailers such
as supermarkets. A point often missed is that community
pharmacy provides an alternative in this retail segment to
dominance by the supermarket sector; its presence pro-
vides some balance, although small, to the current retail
duopoly.
Government initiatives such as the 20 day rule (for certain
PBS medicines a repeat supply of the same medicine
within 20 days will fall outside the Safety Net), increased
patient co-payments (where the patient pays an increased
proportion of the total cost of medicines supplied) and
the increased safety net qualification have all slowed
script volumes and sales. Pharmacists observe that many
consumers do have difficulty in funding pharmaceutical
purchases; this is particularly the case for consumers who
do not qualify for a concession card and may be taking
three to five items permanently. The monthly cost for
these consumers is between $100 and $150. The Austral-
ian Pharmaceutical Benefits Scheme provides a significant
subsidy over the total real cost for such pharmaceuticals,
but nevertheless, pharmacists observe first hand the finan-
cial difficulty that many consumers experience. Of major
concern is the unknown impact that failure to take medi-
cines can have on both consumer wellbeing and the over-
all health budget. Non concession card consumers can
obtain some relief if they qualify for a safety net card,
although the dollar target for this still excludes many (in
2007 $ 1059 per annum). The recent 5-year Fourth Com-
munity Pharmacy Agreement was negotiated on the basis
of pharmacist remuneration increasing by 30% over the 5
years. In the first year of the agreement the PBS grew by a
mere 1.7%, while volume actually fell 1% in the same
period. Based on the original estimates for the five years it
is now expected the PBS under spend will be $2 billion.
This $2 billion savings is based on the existing PBS model
and does not take into consideration the new Abbott pro-
posals.
Overheads, particularly pharmacist wages, have increased
at double digit growth rates for the last 3 years due to the
shortage of health professionals [8]. Research shows that
most pharmacies are suffering a downturn in net profits.
This is despite the increased availability of generic drugs
and the generic supply rate increasing from 18% to 25%
(and pharmacists securing better trading terms compared
with branded products). The actual net profit seems to
depend heavily on the improved trading terms. Ironically,
in the future, pharmacies may find they receive a lower
margin with generics than on branded medicines. This
would be a major disincentive to encourage the use of
generics.
The supermarket industry and discount department stores
have been taking market share from pharmacy, selling
non scheduled products, which places more importance
on dispensing and OTC (Over The Counter) medicines.
Viability of Community Pharmacy: impact of 
using generic drug policy to drive down PBS 
costs
Pharmacies are part-Government medicines dispenser
and part-retailer. A typical pharmacy generates sales of
around $2 million per year, and runs at a gross margin of
27%–32% of sales. The major costs for pharmacy are rent
and wages. Rent is a significant issue because pharmacies
are best located in busy retail locations, usually close to
other everyday shopping activities (chore shopping).
Consumers expect easy access to their pharmacy and this
is essential as key pharmacy shoppers are the elderly and
the less mobile.Australia and New Zealand Health Policy 2007, 4:7 http://www.anzhealthpolicy.com/content/4/1/7
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Pharmacist wages are rising because there is an overall
shortage of some 3000 pharmacists in the Australian mar-
ket. Pharmacists are required across extended hours and
during weekends and public holidays. Additionally, Aus-
tralian Pharmacy Boards, which primarily represent the
interests of consumers, mandate that pharmacists should
practice in a safe manner. A safe work load is, according to
most professional organisations, somewhere between 100
and 150 prescriptions per pharmacist during an 8 hour
day. This assumes that the pharmacist in also performing
a range of other tasks: communicating with doctors,
supervising the sale of scheduled medicines, assisting con-
sumers with a wide range of health problems, administer-
ing pharmacotherapy programs and supervising other
staff. A pharmacy technician is also usually present to
assist the pharmacist. Tasks that the technician may
undertake are ordering and packing away stock, clerical
duties, cleaning duties and customer service.
Pharmacies must also provide for other occupancy costs
and maintain the pharmacy in a professional and efficient
manner. Pharmacies should also allocate funds for timely
physical improvements, both ongoing and for major peri-
odic refurbishments. Consumers expect a pharmacy to be
modern, bright and efficient and with enough space to
shop comfortably and importantly to receive confidential
counselling when required. Current refurbishments cost
around $1,000 to $ 2,000 per square metre and with com-
munity pharmacies ranging in size from 250 to 400
square metres, refurbishment costs are significant. Also,
many smaller pharmacies are seeking to increase their cur-
rent footprint and to introduce efficiencies, but expansion
requires access to funding and growth opportunities.
Individual pharmacists invest in pharmacy businesses for
two reasons. Firstly, as a health practitioner, they feel that
even within overarching legislative and professional juris-
dictions, there is still an opportunity to practice their pro-
fession in their preferred style and in effect, make their
own unique offer to consumers. This individuality of offer
is positive for consumers, in that there is an opportunity
to seek out the pharmacist that best suits their needs. Sec-
ondly, pharmacists invest in pharmacy businesses to earn
a return on their investment and to maximise that return
by investing management skills into the business. How-
ever, given that 70% of business activity is PBS prescrip-
tions and that prescription prices to the consumer are
fixed and also that mark up and wholesale prices are fixed,
the pharmacist has little control in driving profitability of
the PBS component of the business.
This is a crucial issue for community pharmacy owners as
they are also facing reduced margins due to current PBS
initiatives, particularly measures that involve the use of
generic medicines, in a climate of almost zero growth.
Pharmacists have virtually no control over the PBS drivers.
Gross Profit has been further eroded by the impact of the
low 10% mark up on expensive drugs and the flat mark up
of $40 for drugs priced over $1,000. Net profit has been
largely positively influenced by trading terms, both gener-
ally and via generic suppliers. As any business owner will
attest, improvements in trading terms are hard earned –
they are usually a reward for loyalty and efficient purchas-
ing practices.
Pharmacists have traditionally offered consumers a range
of services which complements the core activity of dis-
pensing. Consumers have enjoyed low cost or free filling
of Dose Administration Aids, free delivery to the less
mobile, support services for nursing homes and signifi-
cant free advice to consumers, often without the sale of a
product. These services have been provided out of the
'general profitability' of funds available to the pharmacy
business owner.
Further reduction in margin on prescriptions would
render many of these services unviable. In order for phar-
macies to maintain liquidity, major changes to the cost
structure of pharmacies would need to be implemented.
The first option would be to reduce the number of phar-
macists in pharmacy, thereby changing the practice of
pharmacy as we know it. Pharmacies would become 'sau-
sage factories' churning out prescriptions, with very little
time to counsel patients. The second option may be to
introduce fees for services currently provided at no cost.
When price is the only determinant, does the consumer
receive the best service and the best outcome? Observa-
tions in other countries indicate a paucity of service levels.
Pharmacists may also look to expand their retail sales, in
effect using the PBS traffic to create profitable non-pre-
scription sales.
It will not be possible for a retail solution to save pharma-
cies, so that they may continue to supply PBS prescrip-
tions on behalf of the government. It is probable that
many pharmacies would suffer severe financial hardship
forcing closure, or reach such a low state of profitability
that they may be unable to provide a wide range of serv-
ices. Some pharmacies may find that their way forward
would be to focus almost solely on retail sales, with very
little or no advice available on prescriptions.
Concluding discussion
Although the PBS is in decline in terms of prescriptions
dispensed and PBS expenditure is growing more slowly
than the economy, the government continues to reform
the PBS, via a series of initiatives, mostly centering on
changes to generic medicines. New drugs are only added
to the PBS if they satisfy a rigorous cost benefit analysis,Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Australia and New Zealand Health Policy 2007, 4:7 http://www.anzhealthpolicy.com/content/4/1/7
Page 7 of 7
(page number not for citation purposes)
and they are most often priced at the therapeutic group
bench mark price. The imposition of mandatory price cuts
each time a generic is listed on the PBS may well start to
lessen the interest of generic companies in listing their
products.
The financial effect on community pharmacy will not be
known for some time but the recent reforms will deliver
new financial dynamics into every pharmacy business.
Community pharmacy, because of its core activity of sup-
plying PBS prescriptions, is already showing nil or nega-
tive growth. Mandatory counselling services provided by
pharmacy may be lost if pharmacy owners need to reduce
the number of pharmacists employed. Consumers have a
right to enjoy contemporary pharmacy services in Aus-
tralia and these services cannot happen unless a satisfac-
tory financial business model is in place.
The future of generic drug supply via the PBS is critically
important to ensure a cost effective and competitive drug
supply pipeline for Australians, to allow for new and
expensive drugs to be listed on the PBS when appropriate
and to allow consumers access to medications at the low-
est possible price. The current PBS reforms will deliver
price transparency for each generic supplied to pharmacy
and the true cost price of each drug will be known to all
parties. Historically, the discounts given by generic manu-
facturers to pharmacists have become part of the overall
profit mix of the pharmacy. New incentive payments have
been introduced so that pharmacists will be able to
replace some part of the forgone generic discounts, and it
is hoped that this new overall profit figure will continue
to underpin the services that pharmacy offers to consum-
ers. This subtle shift of identifying the lowest actual cost of
a drug, with full transparency, may lead to clearer recogni-
tion of the range of professional services that a pharmacist
provides in every patient/pharmacist interaction. The cost
of such professional services may be debated more fully in
the future and the quantification of these services will rec-
ognise the finite capacity of the pharmacist and the real
costings in the Australian setting.
Community pharmacy is unsure whether the new incen-
tive payments will be an adequate compensation, how-
ever it recognises that generic price transparency will be a
standard practice and that generic manufacturers, perhaps
the most directly affected by the new reforms, will offer
significantly different trading terms to the trading terms
experienced more recently.
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